Drug Profile
Research programme: metabotropic glutamate receceptor-2 modulators - sanofi-aventis
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class
- Mechanism of Action Metabotropic glutamate receptor 2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in France (PO)
- 13 Nov 2010 Preclinical trials in Schizophrenia in France (PO)